High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

Miró, J.M.; Entenza, J.M.; Del Río, A.; Velasco, M.; Castañeda, X.; Garcia de la Mària, C.; Giddey, M.; Armero, Y.; Pericàs, J.M.; Cervera, C.; Mestres, C.A.; Almela, M.; Falces, C.; Marco, F.; Moreillon, P.; Moreno, A.

doi:10.1128/AAC.06449-11

High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

Details

Request a copy

Serval ID

serval:BIB_7B56DF392269

Type

Article: article from journal or magazin.

Collection

Publications

Institution

UNIL/CHUV

Title

High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

Journal

Antimicrobial Agents and Chemotherapy

Author(s)

Miró J.M., Entenza J.M., Del Río A., Velasco M., Castañeda X., Garcia de la Mària C., Giddey M., Armero Y., Pericàs J.M., Cervera C., Mestres C.A., Almela M., Falces C., Marco F., Moreillon P., Moreno A.

Working group(s)

Hospital Clinic Experimental Endocarditis Study Group

Contributor(s)

Miró JM., Moreno A., del Río A., Cervera C., Pericas JM., Castañeda X., Gatell JM., Marco F., Garcia de la Mària C., Armero Y., Almela M., Jiménez-de-Anta MT., Mestres CA., Paré JC., Falces C., Cartañá£££Ramón£££ R. , Ninot S., Azqueta M., Sitges M., Heras M., Pomar JL., Ramírez J., Ribalta T., Brunet M., Soy D., Perez I.

ISSN

1098-6596 (Electronic)

ISSN-L

0066-4804

Publication state

Published

Issued date

2012

Peer-reviewed

Oui

Volume

Number

Pages

4511-4515

Language

english

Notes

Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Abstract

We describe 3 patients with left-sided staphylococcal endocarditis (1 with methicillin-susceptible Staphylococcus aureus [MSSA] prosthetic aortic valve endocarditis and 2 with methicillin-resistant S. aureus [MRSA] native-valve endocarditis) who were successfully treated with high-dose intravenous daptomycin (10 mg/kg/day) plus fosfomycin (2 g every 6 h) for 6 weeks. This combination was tested in vitro against 7 MSSA, 5 MRSA, and 2 intermediately glycopeptide-resistant S. aureus isolates and proved to be synergistic against 11 (79%) strains and bactericidal against 8 (57%) strains. This combination deserves further clinical study.

Keywords

Aged, Anti-Bacterial Agents/administration & dosage, Anti-Bacterial Agents/adverse effects, Daptomycin/administration & dosage, Daptomycin/adverse effects, Drug Synergism, Drug Therapy, Combination, Endocarditis, Bacterial/drug therapy, Female, Fosfomycin/administration & dosage, Fosfomycin/adverse effects, Humans, Male, Methicillin-Resistant Staphylococcus aureus/drug effects, Microbial Sensitivity Tests, Middle Aged, Staphylococcal Infections/drug therapy, Staphylococcal Infections/microbiology

OAI-PMH

oai:serval.unil.ch:BIB_7B56DF392269

DOI

10.1128/AAC.06449-11

Pubmed

22644033

Web of science

000306826300066

Open Access

Yes

Create date

01/11/2012 19:44